Asia Pacific Bladder Cancer Diagnostics Market Trends, Growth, Size, Challenges and Future Outlook
Asia Pacific Bladder Cancer Diagnostics Market Growth, Trends, Analysis, Size- By Test Type, By Stages, By Cancer Type, By End User, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: May-2023 | Report ID: HLCA2340 | Pages: 1 - 154 | Formats*: |
| Category : Healthcare | |||
Asia Pacific Bladder Cancer Diagnostics Market Overview
According to SPER Market Research, the Asia Pacific Bladder Cancer Diagnostics Market is estimated to reach USD XX billion by 2033 with a CAGR XX%.
The onset of bladder cancer occurs when normal cells in the lining of the bladder, primarily urothelial cells, undergo a transformation and uncontrolled growth, resulting in the formation of a mass known as a tumor. Urothelial cells also line the renal pelvis, ureters, and urethra. Consequently, cancer originating in the renal pelvis and ureters is categorized as a form of urothelial cancer, often referred to as upper tract urothelial cancer. Generally, this type of cancer is treated similarly to bladder cancer, as described in this guide. Tumors can be classified as either cancerous or benign. A cancerous tumour is considered malignant, as it has the ability to grow and spread to other parts of the body. Conversely, a benign tumour can grow but not advance. It is important to note that benign bladder tumors are exceedingly uncommon.
Exploring the Growth Drivers of the Asia Pacific Bladder Cancer Diagnostics Industry
The global incidence of bladder cancer is increasing, with most gene mutations associated with the disease occurring during a person's lifetime rather than being inherited. Exposure to cancer-causing chemicals or radiation, such as those found in tobacco smoke, can contribute to these acquired gene mutations. However, some gene changes may happen randomly within cells. Bladder cancer is predominantly seen in older individuals, with around 90% of cases occurring in people over 55 years old. The growing number of bladder cancer cases has led to an increased demand for bladder cancer diagnostic products, driving the growth of the Asia Pacific bladder cancer diagnostics market. Awareness of bladder cancer and the importance of early diagnosis are emphasized during the nationally recognized Bladder Cancer Awareness Month in the U.S. in May. Despite being less common than other cancers, bladder cancer affects over 720,000 patients in the U.S. Efforts are being made to advance research, patient care, education, and the development of innovative treatments for bladder tumour patients, particularly in the Asia-Pacific region, amid the ongoing COVID-19 crisis. The rising awareness of early bladder cancer diagnosis plays a significant role in propelling the Asia Pacific bladder cancer diagnostic market expansion.
What challenges does the Asia Pacific Bladder Cancer Diagnostics Market face?
Chemotherapy is a cancer treatment that uses drugs administered through the veins or orally to reach cancer cells throughout the body. However, some chemotherapy drugs cannot effectively enter the bladder to treat bladder cancer. Intravesical immunotherapy, such as Bacillus Calmette-Guerin (BCG), is commonly used for early-stage bladder cancer. BCG, a harmless bacterium related to the one causing tuberculosis, activates immune system cells in the bladder, prompting them to attack cancer cells. Chemotherapy drugs can have various side effects, including hair loss, mouth sores, nausea, fatigue, and increased infection risk. Certain drugs may cause kidney damage and hearing loss. These side effects may limit the growth of the Asia-Pacific bladder cancer diagnostics market.
In what ways has the COVID-19 pandemic affected Asia Pacific Bladder Cancer Diagnostics Market?
The Asia-Pacific bladder cancer diagnostics market has been negatively affected by the COVID-19 pandemic due to lockdown restrictions, resulting in reduced hospital visits and treatment delays. However, government support, advancements in imaging techniques, and increased collaborations among market players present opportunities for market growth. Despite the initial impact of the pandemic, the market has shown significant growth since reopening, and further expansion is expected. Market players are actively engaged in improving imaging techniques for early bladder cancer detection, bringing advancements and innovation to the market.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Test Type, By Stages, By Cancer Type, By End User, By Distribution Channel |
| Regions covered | Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Thailand, Rest of Asia Pacific |
| Companies Covered | Abbott, Agilent Technologies Inc., Ambu A/S, Bio-Rad Laboratories Inc., Canon Medical Systems Corporation, Cepheid, F. Hoffmann-La Roche Ltd, Fujifilm Corporation, General Electric Company, Hologic Inc., Illumina Inc., Koninklijke Philips N.V., Merck KGaA, MinFound Medical Systems Co, Neusoft Corporation, QIAGEN, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Time Medical Holding, Others |
Key Target Audience:
- Healthcare Insurance Providers
- Healthcare IT and Software Providers
- Healthcare Providers
- Medical Device Manufacturers
- Patient Advocacy Groups
- Pharmaceutical and Biotechnology Companies
Asia Pacific Bladder Cancer Diagnostics Market Segmentation:
1. By Test Type:
- Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Test Type, 2023-2033
- Biopsy
- Cystoscopy
- Imaging test
- Urine lab test
- Others
2. By Stages:
- Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Stages, 2023-2033
- Stage I
- Stage II
- Stage III
- Stage IV
3. By Cancer Type:
- Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Cancer Type, 2023-2033
- Squamous Cell Bladder Cancer
- Transitional Cell Bladder Cancer
- Other Cancer Types
4. By End User:
- Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By End User, 2023-2033
- Associated Labs
- Cancer Research Institutes
- Diagnostic Imaging Centers
- Hospital
- Independent Diagnostic Laboratories
5. By Region:
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Thailand
- Rest of Asia Pacific
Key Topics Covered in the Report:
- Asia Pacific Bladder Cancer Diagnostics Market Size (FY’2023-FY’2033)
- Overview of Asia Pacific Bladder Cancer Diagnostics Market
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By Test Type (Biopsy, Cystoscopy, Imaging test, Urine lab test, Others)
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By Stages (Stage I, Stage II, Stage III, Stage IV)
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By Cancer Type (Squamous Cell Bladder Cancer, Transitional Cell Bladder Cancer, Other Cancer Types)
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By End User (Associated Labs, Cancer Research Institutes, Diagnostic Imaging Centers, Hospital, Independent Diagnostic Laboratories)
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By Distribution Channel (Direct Tender, Retail Sales)
- Statistical Snap of Asia Pacific Bladder Cancer Diagnostics Market
- Growth Analysis of Asia Pacific Bladder Cancer Diagnostics Market
- Problems and Challenges in Asia Pacific Bladder Cancer Diagnostics Market
- Competitive Landscape in the Asia Pacific Bladder Cancer Diagnostics Market
- Impact of COVID-19 and Demonetization on Asia Pacific Bladder Cancer Diagnostics Market
- Details on Recent Investment in Asia Pacific Bladder Cancer Diagnostics Market
- Competitive Analysis of Asia Pacific Bladder Cancer Diagnostics Market
- Key Players in the Asia Pacific Bladder Cancer Diagnostics Market
- SWOT Analysis of Asia Pacific Bladder Cancer Diagnostics Market
- Asia Pacific Bladder Cancer Diagnostics Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Asia Pacific Bladder Cancer Diagnostics Market
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Asia Pacific Bladder Cancer Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Asia Pacific Bladder Cancer Diagnostics Market
7. Asia Pacific Bladder Cancer Diagnostics Market, By Test Type (USD Million)
7.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Test Type, 2023-20337.2. Biopsy7.3. Cystoscopy7.4. Imaging test7.5. Urine lab test7.6. Others
8. Asia Pacific Bladder Cancer Diagnostics Market, By Stages (USD Million)
8.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Stages, 2023-20338.2. Stage I8.3. Stage II8.4. Stage III8.5. Stage IV
9. Asia Pacific Bladder Cancer Diagnostics Market, By Cancer Type (USD Million)
9.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Cancer Type, 2023-20339.2. Squamous Cell Bladder Cancer9.3. Transitional Cell Bladder Cancer9.4. Other Cancer Types
10. Asia Pacific Bladder Cancer Diagnostics Market, By End User (USD Million)
10.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By End User, 2023-203310.2. Associated Labs10.3. Cancer Research Institutes10.4. Diagnostic Imaging Centers10.5. Hospital10.6. Independent Diagnostic Laboratories
11. Asia Pacific Bladder Cancer Diagnostics Market, By Distribution Channel (USD Million)
11.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Distribution Channel, 2023-203311.2. Direct Tender11.3. Retail Sales
12. Asia Pacific Bladder Cancer Diagnostics Market Forecast, 2019-2033 (USD Million)
12.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share
13. Asia Pacific Bladder Cancer Diagnostics Market, By Test Type, 2019-2033 (USD Million)
13.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Test Type (2019-2026)13.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Test Type (2027-2033)
14. Asia Pacific Bladder Cancer Diagnostics Market, By Stages, 2019-2033 (USD Million)
14.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Stages (2019-2026)14.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Stages (2027-2033)
15. Asia Pacific Bladder Cancer Diagnostics Market, By Cancer Type, 2019-2033 (USD Million)
15.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Cancer Type (2019-2026)15.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Cancer Type (2027-2033)
16. Asia Pacific Bladder Cancer Diagnostics Market, By End User, 2019-2033 (USD Million)
16.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by End User (2019-2026)16.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by End User (2027-2033)
17. Asia Pacific Bladder Cancer Diagnostics Market, By Distribution Channel, 2019-2033 (USD Million)
17.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Distribution Channel (2019-2026)17.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Distribution Channel (2027-2033)
18. Asia Pacific Bladder Cancer Diagnostics Market, By Region, 2019-2033 (USD Million)
18.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Region (2019-2026)18.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Region (2027-2033)18.3. Australia18.4. China18.5. India18.6. Indonesia18.7. Japan18.8. Malaysia18.9. Philippines18.10. Singapore18.11. South Korea18.12. Thailand18.13. Rest of Asia Pacific
19. Company Profile
19.1. Abbott19.1.1. Company details19.1.2. Financial outlook19.1.3. Product summary19.1.4. Recent developments19.2. Agilent Technologies Inc.19.2.1. Company details19.2.2. Financial outlook19.2.3. Product summary19.2.4. Recent developments19.3. Ambu A/S19.3.1. Company details19.3.2. Financial outlook19.3.3. Product summary19.3.4. Recent developments19.4. Bio-Rad Laboratories Inc.19.4.1. Company details19.4.2. Financial outlook19.4.3. Product summary19.4.4. Recent developments19.5. Canon Medical Systems Corporation19.5.1. Company details19.5.2. Financial outlook19.5.3. Product summary19.5.4. Recent developments19.6. Cepheid19.6.1. Company details19.6.2. Financial outlook19.6.3. Product summary19.6.4. Recent developments19.7. F. Hoffmann-La Roche Ltd19.7.1. Company details19.7.2. Financial outlook19.7.3. Product summary19.7.4. Recent developments19.8. Fujifilm Corporation19.8.1. Company details19.8.2. Financial outlook19.8.3. Product summary19.8.4. Recent developments19.9. General Electric Company19.9.1. Company details19.9.2. Financial outlook19.9.3. Product summary19.9.4. Recent developments19.10. Hologic Inc.19.10.1. Company details19.10.2. Financial outlook19.10.3. Product summary19.10.4. Recent developments19.11. Illumina Inc.19.11.1. Company details19.11.2. Financial outlook19.11.3. Product summary19.11.4. Recent developments19.12. Koninklijke Philips N.V.19.12.1. Company details19.12.2. Financial outlook19.12.3. Product summary19.12.4. Recent developments19.13. Merck KGaA19.13.1. Company details19.13.2. Financial outlook19.13.3. Product summary19.13.4. Recent developments19.14. MinFound Medical Systems Co19.14.1. Company details19.14.2. Financial outlook19.14.3. Product summary19.14.4. Recent developments19.15. Neusoft Corporation19.15.1. Company details19.15.2. Financial outlook19.15.3. Product summary19.15.4. Recent developments19.16. QIAGEN19.16.1. Company details19.16.2. Financial outlook19.16.3. Product summary19.16.4. Recent developments19.17. Siemens Healthcare GmbH19.17.1. Company details19.17.2. Financial outlook19.17.3. Product summary19.17.4. Recent developments19.18. Thermo Fisher Scientific Inc.19.18.1. Company details19.18.2. Financial outlook19.18.3. Product summary19.18.4. Recent developments19.19. Time Medical Holding19.19.1. Company details19.19.2. Financial outlook19.19.3. Product summary19.19.4. Recent developments19.20. Others
20. List of Abbreviations
21. Reference Links
22. Conclusion
23. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Asia Pacific Bladder Cancer Diagnostics Market CAGR of XX% during the forecast period.
You can get the sample pages by clicking the link -Click Here
Asia Pacific Bladder Cancer Diagnostics Market size is USD XX billion from 2023 to 2033.
Asia Pacific Bladder Cancer Diagnostics Market Segment is Covered By Test Type, By Stages, By Cancer Type, By End User, By Distribution Channel
The Asia Pacific region is anticipated to have the highest market share in Asia Pacific Bladder Cancer Diagnostics Market.
The key players in the market include Companies Covered Abbott, Agilent Technologies Inc., Ambu A/S, Bio-Rad Laboratories Inc., Canon Medical Systems Corporation, Cepheid, F. Hoffmann-La Roche Ltd, Fujifilm Corporation, General Electric Company, Hologic Inc., Illumina Inc., Koninklijke Philips N.V., Merck KGaA, MinFound Medical Systems Co, Neusoft Corporation, QIAGEN, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Time Medical Holding, Others
The growing number of bladder cancer cases has led to an increased demand for bladder cancer diagnostic products, driving the growth of the Asia Pacific bladder cancer diagnostics market.
Asia Pacific Bladder Cancer Diagnostics Market is projected to reach USD XX billion by 2033, growing at a CAGR of XX% during the forecast period.
Asia Pacific Bladder Cancer Diagnostics Market grew in market size from 2023. The Market is expected to reach USD XX billion by 2033, at a CAGR of XX% during the forecast period.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
